- AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 fold
- Modi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer
Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant technology has started. The trial, run by partner Scancell Holdings plc (AIM: SCLP, “Scancell”) is a multicentre clinical trial, testing the Moditope® vaccine Modi1. This first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer using the AMPLIVANT® adjuvant technology to boost immune response to the therapy.